JAKAFI: payments to doctors
Payments that named JAKAFI as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $16M
- Providers
- 15,079
- Transactions
- 86,840
- Average per transaction
- $185
The per-transaction average — $185 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 15,079 providers the average total is $1,064, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Incyte Corporation | $15,971,145 | 99.6% |
| Novartis Pharma AG | $44,614 | 0.3% |
| Novartis | $25,666 | 0.2% |